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ABSTRACT
　Apoptosis is a form of programmed cell death (PCD) characterized by cell shrinkage 
as well as by early and prominent nuclear chromatin condensation. Our understanding 
of the molecular mechanism involved in the final common pathway of apoptosis has 
advanced remarkably in recent years, and it is now well established that a family of 
cysteine proteases called caspases play a pivotal role in the process. On the other hand, 
there is evidence to suggest that there exist PCDs essentially distinct from apoptosis. 
These PCDs (described as apoptosis-like or necrosis-like depending on the extent to 
which they retain the morphological features of apoptosis) are regulated independently 
of caspases. As a natural consequence of the complexity of PCD, it is becoming 
increasingly important to know whether the cell death model of interest is caspase-
dependent or independent. Cell-permeable pancaspase inhibitors such as zAsp-CH2-
DCB and zVAD-fmk are widely used to examine the involvement of caspases in cell 
death models. While examining the caspase-dependence of staurosporine (STS) -induced 
neuroblastoma cell death, I found that zVAD- fmk but not zAsp-CH2-DCB inhibits 
apoptosis, and that in vitro and in vivo caspase assays may give divergent results in the 
presence of zAsp-CH2-DCB. Time course analysis revealed that, in contrast to zVAD-
fmk which constantly inhibited the processing of endogenous caspase substrates, zAsp-
CH2-DCB inhibited substrate processing only for the first few hours after its addition to 
the culture medium. However, when the caspase activity in lysates prepared from cells 
treated with STS and zAsp-CH2-DCB was measured in vitro, quite unexpectedly, it was 
found that zAsp-CH2-DCB completely inhibited the STS-mediated activation of 
caspases throughout the observation period even when it apparently failed to inhibit the 
processing of caspase substrates within intact cells. These findings together suggest that 
there exists a cellular mechanism that inactivates zAsp-CH2-DCB in a reversible 
manner. This reversible inactivation was an active, intracellular process requiring de 
novo protein synthesis that inhibited by protein synthesis inhibitor cycloheximide. And 
the inactivation was observed in another human cancer cell line HeLa and with 
different apoptotic stimuli such as UV irradiation. These results have important 
implications that require consideration when designing experiments involving the use of 
caspase inhibitors as well as interpreting their results. 
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